Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
French Innovative Leukemia Organisation
With
Mundipharma Pte Ltd.
The primary objective of this study is to define the activity of Bendamustine for the treatment of T cells lymphomas. The activity of Bendamustine is determined by the response rate (RR) to the treatment within 22 days after intravenous infusion which enables to get a confidence interval of 95 % for the probability of an overall response rate (ORR).
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients aged more than 18 years.
Refractory or relapsed peripheral T-cell NHL (PTCL)
Cutaneous T cell lymphoma (CTCL) in relapse or refractory to topical therapy
ECOG score less than 2
No major organ dysfunction unrelated to lymphoma.
You may not be if
Pregnant or breast feeding women
ECOG score \> 2
Estimate survival time \< 3 months
Active infection or severe organ dysfunction or psychiatric condition that unable patients to receive chemotherapy
Creatinine clearance \< 10 ml/min or severe hepatic dysfunction not related to lymphoma.
Previous chemotherapy/immunotherapy within 3 weeks before study entry
Known seropositive for or active viral infection HIV, EBV, HCV
